Related Experiment Video

Updated: Aug 5, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Effectiveness of Recombinant Human Growth Hormone Therapy in Small-for-Gestational-Age Children With Short Stature: A

Sanghee Park1, Yena Lee2, Hwal Rim Jeong3

  • 1Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital, Seoul, Republic of Korea.

Clinical Endocrinology
|August 2, 2026
PubMed

Insights

Pathogenic genetic variants impact growth outcomes in children with persistent short stature. While recombinant human growth hormone (rhGH) therapy helps, those with variants show a slower growth response over time, emphasizing genetic evaluation for personalized treatment.

Area of Science:

  • Pediatric Endocrinology
  • Genetics
  • Growth Disorders

Background:

  • Children born small for gestational age with persistent short stature (SGA-SS) often exhibit growth challenges.
  • Genetic factors can significantly influence growth patterns and response to therapy.

Purpose of the Study:

  • To assess the influence of pathogenic genetic variants on growth outcomes in SGA-SS children treated with recombinant human growth hormone (rhGH) for three years.
  • To compare growth trajectories between genetically characterized SGA-SS patient groups.

Main Methods:

  • Retrospective cohort study of 179 SGA-SS children.
  • Classification into variant-positive (n=30) and variant-negative (n=149) groups based on genetic evaluation.
  • Longitudinal assessment of clinical characteristics and growth outcomes over 3 years of rhGH therapy using linear mixed models.

Main Results:

  • Variant-positive children had lower baseline height SDS and higher rates of intellectual disability and congenital anomalies.
  • rhGH therapy improved height SDS in both groups after 3 years.
  • A progressive attenuation of height SDS gain was observed in the variant-positive group over the treatment period.

Conclusions:

  • rhGH therapy is effective for linear growth in SGA-SS children.
  • Genetic evaluation is crucial as pathogenic variants are associated with lower baseline stature and reduced growth response to rhGH.
  • Personalized treatment strategies informed by genetic findings are important for optimizing growth outcomes in SGA-SS patients.
Abstract

Keywords:
genetic variantsgrowth hormoneshort staturesmall for gestational age

More Related Videos

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model08:03

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model

Published on: November 4, 2025

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Polygenic Traits01:18

Polygenic Traits

When more than one gene is responsible for a given phenotype, the trait is considered polygenic. Human height is a polygenic trait. Studies have uncovered hundreds of loci that influence height, and there are believed to be many more. Due to the high number of genes involved, as well as environmental and nutritional factors, height varies significantly within a given population. The distribution of height forms a bell-shaped curve, with relatively few individuals in the population at the...
What is Genetic Engineering?00:49

What is Genetic Engineering?

Overview
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...